Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 46–57 | Cite as

Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor

  • Nino Porakishvili
  • Ketki Vispute
  • Andrew J. Steele
  • Nadeeka Rajakaruna
  • Nina Kulikova
  • Tamar Tsertsvadze
  • Amit Nathwani
  • Rajendra N. Damle
  • Edward A. Clark
  • Kanti R. Rai
  • Nicholas Chiorazzi
  • Peter M. Lydyard
Research Article

Abstract

Chronic lymphocytic leukemia (CLL) development and progression are thought to be driven by unknown antigens/autoantigens through the B cell receptor (BCR) and environmental signals for survival and expansion including toll-like receptor (TLR) ligands. CD180/RP105, a membrane-associated orphan receptor of the TLR family, induces normal B cell activation and proliferation and is expressed by approximately 60% of CLL samples. Half of these respond to ligation with anti-CD180 antibody by increased activation/phosphorylation of protein kinases associated with BCR signaling. Hence CLL cells expressing both CD180 and the BCR could receive signals via both receptors. Here we investigated cross-talk between BCR and CD180-mediated signaling on CLL cell survival and apoptosis. Our data indicate that ligation of CD180 on responsive CLL cells leads to activation of either prosurvival Bruton tyrosine kinase (BTK)/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT-mediated, or proapoptotic p38 mitogenactivated protein kinase (p38MAPK)-mediated signaling pathways, while selective immunoglobulin M (sIgM) ligation predominantly engages the BTK/PI3K/AKT pathway. Furthermore, pretreatment of CLL cells with anti-CD180 redirects IgM-mediated signaling from the prosurvival BTK/PI3K/AKT toward the proapoptotic p38MAPK pathway. Thus preengaging CD180 could prevent further prosurvival signaling mediated via the BCR and, instead, induce CLL cell apoptosis, opening the door to therapeutic profiling and new strategies for the treatment of a substantial cohort of CLL patients.

Notes

Acknowledgments

The research was funded by the University of Westminster, London, UK. We are grateful to the CLL patients who consented to participate in this project. The research was supported in part by RO1 grant CA 081554 from the NIH National Cancer Institute to N Chiorazzi.

References

  1. 1.
    Ghia P, Ferreri AM, Caligaris-Cappio F. (2007) Chronic lymphocytic leukemia. Crit. Rev. Oncol. Hemato. 64:234–46.CrossRefGoogle Scholar
  2. 2.
    Chiorazzi N, Ferrarini M. (2003) B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21:841–94.CrossRefGoogle Scholar
  3. 3.
    Ghia P, Chiorazzi N, Stamatopoulos K. (2008) Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J. Int. Med. 264:549–62.CrossRefGoogle Scholar
  4. 4.
    Porakishvili N, et al. (2005) Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br. J. Haematol. 131:313–9.CrossRefGoogle Scholar
  5. 5.
    Porakishvili N, et al. (2011) CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells. Br. J. Haematol. 153:486–98.CrossRefGoogle Scholar
  6. 6.
    Decker T, et al. (2000) Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp. Hematol 28:558–68.CrossRefGoogle Scholar
  7. 7.
    Jahrsdörfer B, et al. (2001) CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69:81–8.PubMedGoogle Scholar
  8. 8.
    Bernasconi NL, Onai N, Lanzavecchia A. (2003) A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 101:4500–4.CrossRefGoogle Scholar
  9. 9.
    Tromp JM, et al. (2010) Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene. 29:5071–82.CrossRefGoogle Scholar
  10. 10.
    Muzio M, Fonte E, Caligaris-Cappio F. (2012) Tolllike receptors in chronic lymphocytic leukemia. Mediterr. J. Hematol. Infect. Dis. 4:e2012055.CrossRefGoogle Scholar
  11. 11.
    Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter J.A. (1988) Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J. Immunol. 140:4071–8.PubMedGoogle Scholar
  12. 12.
    Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. (1995) RP105, a novel B cell surface molecule 56 implicated in B cell activation, is a member of the leucine-rich repeat protein family. J. Immunol. 154:3333–40.PubMedGoogle Scholar
  13. 13.
    Otipoby KL, Nagai Y, Shu GL, Miyake K, Clark EA. (2002) CD180 (RP105/Bgp95) Workshop Report In: Mason D.Y., ed. Leukocyte Typing VII. White Cell Differentiation Antigens. Oxford University Press; p. 120–3.Google Scholar
  14. 14.
    Ogata H, et al. (2000) The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J. Exp. Med. 192:23–9.CrossRefGoogle Scholar
  15. 15.
    Miura Y, et al. (1998) RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood. 92:2815–22.PubMedGoogle Scholar
  16. 16.
    Chaplin JW, Kasahara S, Clark EA, Ledbetter JA. (2011) Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway. J. Immunol. 187:4199–209.CrossRefGoogle Scholar
  17. 17.
    Longo PG, et al. (2007) The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 21:110–20.CrossRefGoogle Scholar
  18. 18.
    De Frias M, et al. (2009) Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 94:1698–707.CrossRefGoogle Scholar
  19. 19.
    Bernal A, et al. (2001) Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 98:3050–7.CrossRefGoogle Scholar
  20. 20.
    Allsup DJ, et al. (2005) B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res. 65:7328–37.CrossRefGoogle Scholar
  21. 21.
    Burger JA, et al. (2009) High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 113:3050–8.CrossRefGoogle Scholar
  22. 22.
    Quiroga MP, et al. (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 114:1029–37.CrossRefGoogle Scholar
  23. 23.
    Packham G, Stevenson F. (2010) The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin. Cancer Biol. 20:391–9.CrossRefGoogle Scholar
  24. 24.
    Petlickovski A, et al. (2005) Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 105:4820–7.CrossRefGoogle Scholar
  25. 25.
    Steele AJ, et al. (2010) The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood. 116:4569–77.CrossRefGoogle Scholar
  26. 26.
    Zhuang J, et al. (2010) Akt is activated in chronic lymphocytic leukemia cells and delivers a prosurvival signal: the therapeutic potential of Akt inhibition. Haematologica. 95:110–8.CrossRefGoogle Scholar
  27. 27.
    Herman SE, et al. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117:6287–96.CrossRefGoogle Scholar
  28. 28.
    Barragan M, et al. (2002) Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood. 99:2969–76.CrossRefGoogle Scholar
  29. 29.
    Barragan M, Campas C, Bellosillo B, Gil J. (2003) Protein kinases in the regulation of apoptosis in B-cell chronic lymphocytic leukemia. Leuk. Lymphoma. 44:1865–70.CrossRefGoogle Scholar
  30. 30.
    Barragan M, et al. (2006) Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase Cb. J. Leukoc. Biol. 80:1473–9.CrossRefGoogle Scholar
  31. 31.
    Nedellec S, et al. (2005) B cell response to surface IgM cross-linking identifies different prognostic groups of B chronic lymphocytic leukemia patients. J. Immunol. 174:3749–56.CrossRefGoogle Scholar
  32. 32.
    Wickremasinghe RG, Prentice AG, Steele AJ. (2011) Aberrantly activated anti-apoptotic signaling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets. Br. J. Haematol. 153:545–56.CrossRefGoogle Scholar
  33. 33.
    Scuppoli MT, Pizzolo G. (2012) Signaling pathways activated by the B cell receptor in chronic lymphocytic leukemia. Expert Rev. Hematol. 5:341–8.CrossRefGoogle Scholar
  34. 34.
    Yamashita Y, et al. (1996) Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor colligation. J. Exp. Med. 184:113–20.CrossRefGoogle Scholar
  35. 35.
    Woodland RT, et al. (2008) Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood. 111:750–60.CrossRefGoogle Scholar
  36. 36.
    Downward J. (2004) PI 3-kinase, Akt and cell survival. Semin. Cell. Dev. Biol. 15:177–82.CrossRefGoogle Scholar
  37. 37.
    Longo PG, et al. (2008) The Akt/Mcl-1pathway plays a prominent role in mediating anti-apoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 111:846–55.CrossRefGoogle Scholar
  38. 38.
    Packham G, et al. (2014) The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 99:1138–48.CrossRefGoogle Scholar
  39. 39.
    Burger JA, et al. (2010) The Bruton’s tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood. 116:32a.CrossRefGoogle Scholar
  40. 40.
    Ponader S, et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 119:1182–9.CrossRefGoogle Scholar
  41. 41.
    Efremov DG, Gobessi S, Longo PG. (2007) Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun. Rev. 7:102–8.CrossRefGoogle Scholar
  42. 42.
    Manning BD, Cantley LC. (2007) AKT/PKB signaling: navigating downstream. Cell. 129:1261–74.CrossRefGoogle Scholar
  43. 43.
    Okkenhaug K., Ali K, Vanhaesebroeck B. (2007) Antigen receptor signaling: a distinctive role for the p110d isoform of PI3K. Trends Immunol. 28:80–7.CrossRefGoogle Scholar
  44. 44.
    Herman SE, et al. (2010) Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 116:2078–88.CrossRefGoogle Scholar
  45. 45.
    Cuni S, et al. (2004) A sustained activation of PI3K/NFkappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 18:1391–400.CrossRefGoogle Scholar
  46. 46.
    Ringshausen I, et al. (2002) Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase CD. Blood. 100:3741–8.CrossRefGoogle Scholar
  47. 47.
    Plate JM. (2004) PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase8 activation. Leuk. Lymphoma. 45:1519–29.CrossRefGoogle Scholar
  48. 48.
    Lannutti BJ, et al. (2011) CAL-101, a p110 {delta} selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117:591–4.CrossRefGoogle Scholar
  49. 49.
    Yazawa N, et al. (2003) CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 102:1374–80.CrossRefGoogle Scholar
  50. 50.
    Chan VW, et al. (1998) The molecular mechanism of B cell activation by toll-like receptor protein RP-105. J. Exp. Med. 188:93–101.CrossRefGoogle Scholar
  51. 51.
    Hebeis B, Vigorito E, Kovesdi D, Turner M. (2005) Vav proteins are required for B lymphocyte responses to LPS. Blood. 106:635–40.CrossRefGoogle Scholar
  52. 52.
    Takeshita F, et al. (2004) Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin. Immunol. 16:17–22.CrossRefGoogle Scholar
  53. 53.
    Ahmad-Nejad P, et al. (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32:1958–68.CrossRefGoogle Scholar
  54. 54.
    Park Y, Lee SW, Sung YC. (2002) Cutting edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-30-OH kinase pathway. J. Immunol. 168:5–8.CrossRefGoogle Scholar
  55. 55.
    Peng SL. (2005) Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol. 17:230–6.CrossRefGoogle Scholar
  56. 56.
    Yi AK, Yoon JG, Krieg AM. Convergence of CpG DNA- and BCR mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int. Immunol. 2003; 15:577–91.CrossRefGoogle Scholar
  57. 57.
    Grumont RJ, et al. (1998) B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J. Exp. Med. 187:663–74.CrossRefGoogle Scholar
  58. 58.
    Piatelli MJ, et al. (2004) Phosphatidylinositol 3-kinase-dependent mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 and NF-kappa B signaling pathways are required 57 for B cell antigen receptor-mediated cyclin D2 induction in mature B cells. J. Immunol. 172:2753–62.CrossRefGoogle Scholar
  59. 59.
    Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164:2200–6.CrossRefGoogle Scholar
  60. 60.
    Ntoufa S, et al. (2012) Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol. Med. 18:1281–91.CrossRefGoogle Scholar
  61. 61.
    Negro R, et al. (2012) Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood. 119:6278–87.CrossRefGoogle Scholar
  62. 62.
    Fukuda M, Kojima T, Kabayama H, Mikoshiba K. (1996) Mutation of the pleckstrin homology domain of Bruton’s tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol. Chem. 271:30303–6.CrossRefGoogle Scholar
  63. 63.
    Khan WN, et al. (1995) Defective B cell development and function in Btk-deficient mice. Immunity. 3:283–99.CrossRefGoogle Scholar
  64. 64.
    Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. (2000) Bruton’s tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J. Exp. Med. 191:1735–44.CrossRefGoogle Scholar
  65. 65.
    Petro JB, Rahman SM, Ballard DW, Khan WN. (2000) Bruton’s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J. Exp. Med. 191:1745–54.CrossRefGoogle Scholar
  66. 66.
    Chaplin JW, Chappell CP, Clark EA. (2013) Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation and immunologic memory. J. Exp. Med. 210:2135–46.CrossRefGoogle Scholar
  67. 67.
    Ferrarini M, Totero D, Colombo M, Cutrona G. (2014) Facts and speculations on the onset and clonal expansion of chronic lymphocytic leukemia cells. Int. Trends Immunity. 2:1–10.Google Scholar
  68. 68.
    Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukaemia. Trends Immunol. 2013; 34:592–601.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Nino Porakishvili
    • 1
  • Ketki Vispute
    • 1
  • Andrew J. Steele
    • 2
  • Nadeeka Rajakaruna
    • 1
  • Nina Kulikova
    • 1
    • 3
  • Tamar Tsertsvadze
    • 3
  • Amit Nathwani
    • 4
  • Rajendra N. Damle
    • 5
  • Edward A. Clark
    • 6
  • Kanti R. Rai
    • 5
  • Nicholas Chiorazzi
    • 5
    • 6
  • Peter M. Lydyard
    • 1
  1. 1.Faculty of Science and TechnologyUniversity of WestminsterLondonUK
  2. 2.University of SouthamptonSouthamptonUK
  3. 3.Javakhishvili Tbilisi State UniversityTbilisiGeorgia
  4. 4.UCL Cancer InstituteUniversity College LondonLondonUK
  5. 5.The Feinstein Institute for Medical ResearchManhassetUSA
  6. 6.University of WashingtonSeattleUSA

Personalised recommendations